Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...320321322323324325326327328329330...10671068»
  • ||||||||||  dexamethasone / Generic mfg.
    Knowledge of Kaposi sarcoma among oncology and HIV providers in Kenya () -  May 12, 2022 - Abstract #AIDS2022AIDS_1359;    
    KS knowledge was assessed using a self-administered structured questionnaire adapted from prior experience in East Africa, which included 38 questions regarding KS classification, morphology, symptomatology, diagnosis and management (example question: true/false, each of the following can be used to effectively treat KS (ART/amputation/chemotherapy/antibiotics/radiation/dexamethasone)... Assessing gaps in KS-specific knowledge among diverse cadres of health professionals may be especially important in resource-limited areas, where burden is high and lower-level cadres are often providing front-line HIV and cancer care.
  • ||||||||||  remdesivir / Generic mfg.
    Drug-drug interactions between antiretrovirals and remdesivir () -  May 12, 2022 - Abstract #AIDS2022AIDS_775;    
    Other treatments for COVID-19 studied here did not demonstrate significant DDIs with ARVs. As new COVID-19 therapeutics emerge, and given the prevalence of HIV worldwide, DDIs with ARVs must continue to be assessed.
  • ||||||||||  dexamethasone / Generic mfg.
    Enrollment change:  A Novel Analgesia Technique for ACL Reconstruction (clinicaltrials.gov) -  May 12, 2022   
    P4,  N=78, Active, not recruiting, 
    Selecting regimens based on patient's comorbidities and comedications is key to optimising treatment. N=120 --> 78
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Enrollment closed, Trial completion date, Trial primary completion date:  B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma (clinicaltrials.gov) -  May 12, 2022   
    P1/2,  N=34, Active, not recruiting, 
    N=120 --> 78 Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Aug 2023 | Trial primary completion date: Dec 2021 --> Jul 2022
  • ||||||||||  solithromycin (CEM-101) / Melinta Therap, Fujifilm Holdings, Sovaldi (sofosbuvir) / Gilead
    Journal:  Biocatalytic Asymmetric Construction of Secondary and Tertiary Fluorides from β-Fluoro-α-ketoacids. (Pubmed Central) -  May 12, 2022   
    The reactivity of HpcH towards these fluoro-donors grants access to enantiopure secondary or tertiary fluorides. In addition to representing the first synthesis of tertiary fluorides via biocatalytic carboligation, the afforded products could improve the diversity of fluorinated building blocks and enable the synthesis of fluorinated drug analogs.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19. (Pubmed Central) -  May 12, 2022   
    A diagnostic and prognostic model, namely IRG classifier, was established based on 8 IRGs that is closely correlated with responses to hydrocortisone and immunosuppression status and might facilitate personalized counseling for specific therapy. When or where access to tocilizumab is a problem, methylprednisolone may be considered as an alternative for the treatment of patients with severe COVID-19.
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems. (Pubmed Central) -  May 12, 2022   
    In the present review, we have summarized some of the most attractive applications of DEX-loaded delivery systems, including liposomes, polymers, hydrogels, nanofibers, silica, calcium phosphate, and hydroxyapatite. This review provides our readers with a broad spectrum of nanomedicine approaches to deliver DEX safely.
  • ||||||||||  budesonide / Generic mfg., methotrexate / Generic mfg.
    Journal:  Gastrointestinal Conditions: Inflammatory Bowel Disease. (Pubmed Central) -  May 12, 2022   
    Surgery (complete resection of involved colon) can be curative in UC. In CD, surgery typically is only used for complications or refractory disease.
  • ||||||||||  Oncocort (pegylated liposomal dexamethasone) / Enceladus
    Review, Journal:  Liposteroid Therapy for Idiopathic Pulmonary Hemosiderosis: A Scoping Review of the Literature. (Pubmed Central) -  May 12, 2022   
    This paper reviews and evaluates the efficacy and safety profile of liposomal dexamethasone 21-palmitate (liposteroid) for the treatment of IPH...Liposteroid represents a potential alternative or supplement to conventional CS therapy, as it appears to be more efficacious and associated with fewer side effects. Larger prospective, controlled trials are necessary to be able to define more precisely the therapeutic role of liposteroid in IPH.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Retrospective data, Journal:  Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19. (Pubmed Central) -  May 12, 2022   
    Further studies are required to explain the association between these 2 tumors and improve treatment selection. A combination of severity-adjusted dexamethasone and tocilizumab for the treatment of severe COVID-19 improved clinical recovery without increasing infectious complications or hindering the immune response against SARS-CoV-2.
  • ||||||||||  methylprednisolone acetate / Generic mfg.
    Trial completion date, Trial primary completion date:  The Use of Intra-articular Corticosteroid Injection to Treat Osteoarthritis of the Carpometacarpal Joint (clinicaltrials.gov) -  May 12, 2022   
    P4,  N=90, Recruiting, 
    A combination of severity-adjusted dexamethasone and tocilizumab for the treatment of severe COVID-19 improved clinical recovery without increasing infectious complications or hindering the immune response against SARS-CoV-2. Trial completion date: Jan 2023 --> Dec 2024 | Trial primary completion date: Jan 2022 --> Dec 2024
  • ||||||||||  triamcinolone acetonide topical / Generic mfg.
    Trial completion date, Trial primary completion date, Surgery:  Safety and Effectiveness of Drop-free Small Incision Cataract Surgery (clinicaltrials.gov) -  May 12, 2022   
    P=N/A,  N=100, Not yet recruiting, 
    SLC38A4 knock out in cell lines recapitulates several features considered important in disease pathogenesis. Trial completion date: Aug 2022 --> Nov 2022 | Trial primary completion date: Aug 2022 --> Nov 2022
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD)
    Trial completion:  Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma (clinicaltrials.gov) -  May 11, 2022   
    P2,  N=41, Completed, 
    Although HIF1A gene polymorphisms were not associated with susceptibility to ITP, the CT genotype at rs11549465 was associated with the sensitivity to glucocorticoid treatment of ITP patients, suggesting that the rs11549465 SNP may contribute to the sensitivity of glucocorticoid treatment in pediatric ITP patients. Terminated --> Completed
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    REAL-WORLD OUTCOMES (RWO) FOR STANDARD OF CARE (SOC) TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) () -  May 11, 2022 - Abstract #COMy2022COMy_171;    
    After patients became tri-exposed, the most common treatment regimens were: carfilzomib+dexamethasone (14%), pomalidomide+dexamethasone+chemotherapy (8%), and ixazomib+lenalidomide+dexamethasone (6%). This retrospective chart review of patients with tri-exposed RRMM in Belgium shows that RWO in terms of OS, PFS and TTNT are poor for these patients, with a median OS of <10 months and highlight the high unmet medical need in this patient population.
  • ||||||||||  Empliciti (elotuzumab) / AbbVie, BMS, Darzalex (daratumumab) / J&J
    TREATMENT EFFICACY OF PROGRESSION FREE SURVIVAL FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA IN GERIATRIC PATIENTS: A NETWORK META-ANALYSIS () -  May 11, 2022 - Abstract #COMy2022COMy_163;    
    To the best of our knowledge, this is the first NMA on R/R MM that includes all regimens currently evaluated in randomized trials in elderly R/R MM. Our findings suggest that a 3-drug regimen containing the lenalidomide-dexamethasone backbone, preferentially combined with anti-MM mAbs daratumumab or elotuzumab, has the highest probability of being ranked as the best treatment in this setting, underlying the role of immunotherapy in MM.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., bendamustine / Generic mfg.
    CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS' ERA () -  May 11, 2022 - Abstract #COMy2022COMy_156;    
    36-82), median age at start of treatment 63.6 years (r.37-86) treated with several lines of treatments (median 6, r. 2-11), every refractory to all the drugs previously received (also Bortezomib), received BVD (B 90 mg/sqm days 1,2; V 1.3 mg/sqm days 1,4,8,11, D 20 mg days 1,2,4,5,8,9,11,12, Pegfilgrastim day +4) every 28 days, until progression...Eight patients have surprisingly achieved a notable PR after failure of novel agents (i.e. Carfilzomib, Daratumumab and Pomalidomide). The triplet Bendamustine-Bortezomib-Dexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, and, in particular cases, it could be considered as a bridge to a second autologous or allogenic SCT, also after failure of novel agents.
  • ||||||||||  lenalidomide / Generic mfg., carfilzomib / Generic mfg.
    ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET () -  May 11, 2022 - Abstract #COMy2022COMy_155;    
    Carfilzomib was well tolerated, with grade 2 anemia in 39%(16/41) of patients, successfully managed by ESAs, without necessity of blood transfusions; 29% (12/41) grade 3-4 neutropenia (pegfilgrastim in primary prophylaxis was given, no ospedalization was required, no septic shocks were observed); 34% (14/41) grade 2, 21% (9/41) grade 3 and 12% (5/41) grade 4 thrombocytopenia, without hemorrhagic events and transfusiondependency. Carfilzomib-Lenalidomide-Dexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, also lenalidomide, and it could be considered as a bridge to a second autologous or allogenic SCT.
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial primary completion date:  RESDEX: Restrictive Use of Dexamethasone in Glioblastoma (clinicaltrials.gov) -  May 11, 2022   
    P=N/A,  N=50, Recruiting, 
    Our findings suggest a treatment benefit with IRd in earlier vs later lines, consistent with results from previous, smaller real-world studies of IRd in RRMM. Trial completion date: Apr 2023 --> Apr 2025 | Trial primary completion date: Apr 2022 --> Apr 2024